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To investigate the influence of infarct location on myocardial 
salvage, technetium-99m isonitrile was injected into 43 patients 
with a first myocardial infarction before early reperfusion ther-
apy. Primary coronary angioplasty was performed in 22 patients 
and successful intravenous thrombolytic therapy was given to 15 
patients, both within 6 h of the onset of chest pain. Patency of the 
infarct-related artery was confirmed by angiography in all 37 
patients. In the remaining six patients (three with and three 
without early thrombolytic therapy) the infarct-related artery 
remained occluded. Single photon emission computed tomography 
was performed within 6 h of the administration of technetium-99m 
isonitrile and repeated at the time of hospital discharge. 
Radionuclide ejection fraction at discharge was significantly 
lower for patients with anterior infarction (0.41 ± 0.12) than for 
those with inferior infarction (0.56 ± 0.09, P < 0.001). Early 
perfusion defect size, a measure of myocardium at risk, was 
greater in patients with anterior than in those with inferior 
Randomized trials (1-6) have clearly shown that throm-
bolytic therapy during acute myocardial infarction is associ-
ated with a significant, but modest, improvement in ventric-
ular function. Several nonrandomized studies (7-10) have 
also shown a beneficial trend with primary percutaneous 
transluminal coronary angioplasty. However, there has been 
debate concerning the influence of infarct location on the 
therapeutic efficacy of thrombolytic therapy. Several studies 
(1,2,11) have shown that the beneficial trend in ejection 
fraction and survival seen in patients receiving thrombolysis 
is more evident in patients with anterior infarction. Other 
reports (3-5) have indicated that patients with either anterior 
or inferior infarction have improved ventricular function 
when treated with thrombolytic therapy. The potential for 
early reperfusion therapy to benefit patients with acute 
inferior myocardial infarction, as opposed to those at higher 
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infarction (52 ± 9% vs. 18 ± 10% of the left ventricle, p = 0.0001) 
as was final defect size (30 ± 20% vs. 9 ± 8%, P < 0.01). The 
change in myocardial perfusion, an estimate of myocardial sal-
vage, was also greater in patients with anterior infarction (24 ± 
16% vs. 10 ± 7%, P < 0.01). However, the proportion of 
jeopardized myocardium salvaged (salvage index) was not signif-
icantly different between patients with anterior or inferior infarc-
tion (0.49 ± 0.34 vs. 0.59 ± 0.35, p = NS). Patients with an 
occluded infarct-related artery demonstrated no significant 
change in myocardial perfusion by change in defect size (0 ± 2%) 
or by salvage index (0.06 ± 0.07). Patients with anterior infarction 
have more myocardium at risk than do patients with inferior 
infarction and, subsequently, more myocardial salvage with 
reperfusion therapy. However, the proportion of jeopardized 
myocardium salvaged is independent of infarct location. 
(J Am Coil CardioI1991;17:1303-8) 
risk with anterior infarction, is an issue with major implica-
tions for the selection of patients for reperfusion therapy. 
The ability to assess the extent of myocardium at risk 
during early myocardial infarction with technetium-99m-
hexakis-2-methox y -i sobu ty 1-i soni trile (technetium -99m 
isonitrile) has been demonstrated in animal models (12-14) 
and in clinical trials (15-17) by injection of technetium-99m 
isonitrile after coronary occlusion. The absence of redistri-
bution of technetium-99m isonitrile enables an evaluation of 
the extent of myocardium at risk without delaying reperfu-
sion therapy (8). In an animal model of acute reperfusion 
(13), defect size measured by injection of technetium-99m 
isonitrile after reperfusion correlates closely with final in-
farct size. In clinical studies (15), ventricular function at the 
time of discharge after myocardial infarction has correlatdd 
closely with the final myocardial defect size measured by 
this technique; ejection fraction and final defect size are both 
indicators of infarct size to some extent. The efficacy of 
reperfusion therapy can therefore be quantitated by measur-
ing the extent of myocardium at risk during acute myocardial 
infarction (before the initiation of thrombolysis or primary 
coronary angioplasty) and comparing this with the final 
defect size assessed at the time of hospital discharge. The 
purpose of this study was to compare the efficacy of early 
reperfusion therapy in patients with anterior or inferior 
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infarction by measuring the extent of myocardium at risk and 
final perfusion defect size. 
Methods 
Study patients. The study group consisted of a consecu-
tive series of patients enrolled in a prospective study of 
technetium-99m isonitrile from June 1987 to November 1989 
who met the following criteria: 1) chest pain of at least 30 
min duration, 2) electrocardiographic (ECG) ST segment 
elevation 2:::0.1 m V in at least two leads in the same vascular 
territory, 3) reperfusion therapy within 6 h of the onset of 
chest pain, and 4) postmenopausal women or men> 18 years 
old. There were 53 patients who met the inclusion criteria. 
Exclusion criteria were: 1) evidence of previous myocardial 
infarction by history or ECG Q waves (three patients); 
2) death or clinical instability preventing acquisition of all 
radionuclide studies (six patients); and 3) true lateral infarc-
tion, as assessed by ECG and contrast ventriculography (one 
patient). The study group, therefore, consisted of 43 pa-
tients, 17 of whom have been included in earlier reports 
(15,19). 
Electrocardiography. ST segment elevation 2:::0.1 m V 
was considered significant. ST segment changes in two 
contiguous precordial leads were classified as indicating 
anterior infarction, whereas changes in leads II, III and a VF 
were classified as indicating inferior infarction. ST segment 
elevation solely in leads I and a VL was classified as showing 
lateral infarction and patients with this finding were excluded 
from the study group. Q waves were considered significant if 
they were 2:::40 ms in duration. 
Thrombolytic therapy. Intravenous thrombolysis was 
performed using previously described methods (1,20) with 
either 100 mg of recombinant tissue-type plasminogen acti-
vator (16 patients) or 250,000 U of streptokinase (2 patients). 
Additional early therapy included heparin, aspirin and beta-
receptor blockade according to the judgment of the staff 
cardiologist. 
Coronary angiography. All patients underwent cardiac 
catheterization during the hospital stay. Patients undergoing 
primary coronary angioplasty (21) underwent immediate 
angiography, whereas patients receiving thrombolysis or no 
therapy generally had angiography deferred until later in the 
hospital course (median 1.0 day; 25th percentile 0.25 day and 
75th percentile 2.5 days). The infarct-related artery was 
identified by analysis of the immediate ECG ST segment 
changes, the site of regional wall motion abnormalities on 
left ventriculography and the coronary angiogram. Coronary 
angiography was performed with use of a standard femoral 
or brachial artery approach. At the time of angiography, 37 
patients had a patent (Thrombolysis in Myocardial Infarction 
[TIMI] grade II or III) infarct-related vessel and 6 patients 
had an infarct-related vessel that remained occluded (TIMI 
grade 0 or I) (20). 
Radionuclide studies. Technetium-99m isonitrile (20 to 30 
mCi) was injected intravenously in all patients during acute 
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myocardial infarction before initiation ofreperfusion therapy 
and again just before hospital discharge. Tomographic radio-
nuclide acquisitions were performed 1 to 6 h later with the 
patient supine and with use of a rotating gamma camera. 
Thirty images were acquired for 40 s each over a 180° arc, 
beginning in the 45° right anterior oblique and ending in the 
left posterior oblique view. 
Technetium-99m isonitrile images were processed with 
use of previously described techniques (15,22). Standard 
back projection algorithms and a Ramp-Hanning filter were 
used to reconstruct the images. Quantitation of the extent of 
left ventricular hypoperfusion was performed using a five 
slice method. Short-axis slices of the left ventricle were 
obtained every 6 mm and normalized to the peak counts in 
the heart for each set of images. Circumferential count 
profiles were generated for representative apical, midven-
tricular and basal slices and two intermediate slices (midway 
between the apex and the midventricle and midway between 
the mid ventricle and the base) by identifying the peak counts 
every 6° around the left ventricle. Quantitation of the perfu-
sion defect as a percent of the left ventricle was performed 
with this five slice modification of our previously described 
three slice method (15). The three slice method correlated 
closely with perfusion defect size in phantom studies (22). A 
similar technique correlated closely with area at risk in an 
animal model of permanent occlusion (12). 
The change in perfusion defect was calculated by sub-
tracting the perfusion defect obtained at hospital discharge 
from that obtained before reperfusion therapy. This change 
is a measure of myocardial salvage. "Salvage index" was 
estimated by dividing the change in perfusion defect by the 
early perfusion defect size (myocardium at risk). When the 
change in perfusion defect was a negative number, "salvage 
index" was set equal to O. Radionuclide angiography was 
performed on all patients before discharge (generally 1 day 
after technetium-99m isonitrile tomographic imaging) using 
the modified in vivo technetium-99m labeling method of red 
blood cells of Callahan et al. (23) and previously described 
techniques (24). 
Statistics. Data are presented as mean values ± SD or 
median values with 25th and 75th percentiles. Comparison 
by infarct location and arterial patency for ejection fraction 
and measurements of myocardial perfusion was performed 
with use of a Wilcoxon rank sum test. Changes in myocardial 
perfusion for a group between immediate presentation and 
hospital discharge were performed with use of a Wilcoxon 
signed rank test. 
Results 
Study group (Table 1). The mean age of the study group 
was 57 ± 12 years (range 30 to 78); there were 36 men and 7 
women. There were 22 patients (12 with anterior, 10 with 
inferior infarction) who underwent successful primary coro-
nary angioplasty (mean time to first balloon inflation was 
3.7 ± 1.3 h) and 15 patients (8 with anterior and 7 with 
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Table 1. Clinical Characteristics of 43 Patients by 
Infarct Location 
Anterior Inferior 
Infarct Infarct 
Wall Wall 
(n = 20) (n = 17) 
Reperfusion therapy 
Thrombolysis 8 7 
PTCA 12 10 
Type of infarction 
Q wave 19 14 
Non-Q wave 
Time to therapy 
~3 h 11 7 
>3 h 9 10 
Occluded 
Infarct-Related 
Artery (n = 6) 
3 
0 
6 
0 
Data indicate number of patients. PTCA = coronary balloon angioplasty. 
inferior infarction) who had successful initial therapy with 
thrombolysis (mean time to initiation was 2.8 ± 1.4 h). 
Successful coronary angioplasty was subsequently per-
formed on 9 of these 15 patients (6 with anterior, 3 with 
inferior infarction; median time 11.7 h, 25th percentile 5.4 h, 
75th percentile 72 h). In three patients angiography demon-
strated an occluded infarct-related artery within 24 h after 
thrombolysis; three other patients with an occluded infarct-
related artery received no early reperfusion therapy. Thus, 
the study group comprised 37 patients with documented 
patency of the infarct-related artery after reperfusion ther-
apy (20 with anterior and 17 with inferior infarction) and 6 
patients (all 6 with inferior infarction) who had documented 
total occlusion (Table 1). In all 20 patients with anterior 
infarction, the left anterior descending artery was the infarct-
related vessel. In 22 of the 23 patients with inferior infarc-
tion, the right coronary artery was the infarct-related vessel; 
1 patient had a left circumflex artery occlusion presenting 
with inferior ST segment elevation. 
Myocardium at risk (Table 2). For the group, the initial 
perfusion defect size assessed before reperfusion therapy 
encompassed 34 ± 19% of the left ventricle. Patients with 
anterior infarction had significantly more myocardium at risk 
as measured by technetium-99m isonitrile than did patients 
Table 2. Radionuclide Studies in 43 Patients by Infarct Location 
Anterior Wall Inferior Wall 
Infarction Infarction 
Ejection fraction 0.41 ± 0.12 0.56 ± 0.09 
Perfusion defect (% LV) 
Acute 52 ± 9 18 ± 10 
Discharge 30 ± 20 9 ± 8 
Acute to discharge 24 ± 16 10 ± 7 
Salvage index* 0.49 ± 0.34 0.59 ± 0.35 
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Figure 1. Perfusion defect size by infarct location and arterial 
patency, as determined before reperfusion therapy (Acute) and at 
discharge (Final) with use of technetium-99m isonitrile tomographic 
imaging. Both infarct locations showed a significant decrease in 
perfusion defect size after reperfusion therapy (p < 0.001 for both); 
however. there was no significant change in patients with an 
occluded infarct -related artery. 
with inferior infarction or patients with an occluded infarct-
related artery (Fig. 1). 
Estimates of infarct size (Table 2). Radionuclide ejection 
fraction obtained at the time of hospital discharge was 0.49 ± 
0.13 for the entire study group; it was significantly higher in 
patients with inferior than in patients with anterior infarction 
(Fig. 2). The final defect size measured with technetium-99m 
isonitrile tomographic imaging at discharge was significantly 
larger in the groups with an anterior infarction or an oc-
cluded infarct-related artery than in the group with inferior 
infarction (Fig. 1). For both infarct location groups, the final 
defect size at discharge was significantly less than that of the 
acute defect (p < 0.001 for both groups) but no significant 
change was noted for the group with an occluded infarct-
related artery (Fig. 1). 
Estimates of myocardial salvage (Table 2). Patients with 
an anterior infarct had a significantly greater change in 
perfusion defect size than did patients with an inferior infarct 
Occluded p Value 
Infarct- Anterior Anterior Inferior 
Related vs. vs. vs. 
Artery Inferior Occluded Occluded 
0.58 ± 0.05 <0.001 <0.01 NS 
19 ± 9 0.0001 <0.001 NS 
19 ± 8 <0.01 NS <0.05 
o ± 2 <0.01 <0.001 0.001 
0.06 ± 0.07 NS <0.001 0.001 
*Sa1vage index = (Acute perfusion defect - Discharge perfusion defect)/Acute perfusion defect. Values are mean ± standard deviation; LV = left ventricle. 
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Figure 2. Comparison of ejection fraction by infarct location and 
arterial patency, as determined by radionuclide angiography at the 
time of discharge. Patients with inferior infarction had a significantly 
higher global ejection fraction (p < 0.001) than did patients with 
anterior infarction. 
and those with an occluded vessel (Fig. 3). Patients with 
inferior infarction did have significantly greater absolute 
myocardial salvage than did patients with an occluded 
infarct-related artery (p = 0.001). The salvage index (change 
in perfusion defect size divided by the amount of myocar-
dium at risk) was not significantly different between patients 
with anterior and inferior infarction; it was significantly 
lower in patients with an occluded vessel (Fig. 4). Among 
Figure 3. The change in perfusion defect size, an estimate of 
myocardial salvage, between acute images (before reperfusion ther-
apy) and discharge images quantitated with technetium-99m isoni-
trile tomography by infarct location. Patients with anterior infarc-
tion had significantly greater salvage (p < 0.01) than did those with 
inferior infarction and myocardial salvage was significantly greater 
for patients with inferior infarction than in those with a persistent 
arterial occlusion (p = 0.001). 
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Figure 4. The salvage index ([Acute perfusion defect - Discharge 
perfusion defect]/Acute perfusion defect), quantitated with techne-
tium-99m isonitrile tomography. There is no difference by infarct 
location. Both groups had a significantly greater salvage index than 
did patients with a persistent arterial occlusion. 
patients with a patent vessel, there was a broad range in both 
the change in perfusion defect size (anterior infarction 3% to 
62%, inferior infarction 1% to 25%) and salvage index 
(anterior infarction 0.06 to 1.0, inferior infarction 0.08 to 
1.0); the range was narrowed for patients with an occluded 
vessel (change in defect size -2% to 3%; salvage index 0 to 
0.14). 
Discussion 
Effect of reperfusion on anterior versus inferior infarction. 
A consistent improvement in ventricular function has been 
difficult to demonstrate in randomized trials of reperfusion 
therapy during acute myocardial infarction. Several studies 
(l ,2, 11) have documented a benefit only in patients with 
anterior infarction. Other randomized trials (3-10) have 
clearly shown benefit in left ventricular function or mortality 
independent of infarct location. Patients with inferior infarc-
tion generally have less myocardium at risk and, as a 
consequence, have a higher early ejection fraction than do 
patients with anterior infarction (25,26); therefore, it may be 
difficult to demonstrate an improvement in left ventricular 
ejection fraction in this group (7). The results of the present 
study support this hypothesis. Perfusion defect size both 
immediately and at discharge was significantly smaller and 
ejection fraction at discharge was significantly higher in 
patients with inferior infarction. The change in perfusion 
defect size after reperfusion therapy, a measure of myocar-
dial salvage, was significantly less for patients with inferior 
infarction. However, the salvage index (the percent salvage 
of the myocardium at risk) was not significantly different for 
both infarct locations. There was no significant change in 
perfusion defect site for patients with an occluded infarct-
related vessel. 
JACC Vol. 17, No.6 
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Role of patency of infarct-related artery. There was a 
wide range in both the change in perfusion defect size and 
the salvage index for patients with anterior and those with 
inferior infarction but not for patients with an occluded 
infarct-related artery. The time-dependent success of reper-
fusion therapy has been well documented and may account 
for some of the differences among these variables; however, 
all patients with documented infarct-related arterial patency 
were treated within 6 h of the onset of symptoms during 
which some clinical benefit may be anticipated (27). The 
variability of collateral circulation to the infarct-related 
artery has been shown to influence the success of reperfu-
sion therapy in preserving ventricular function (28) and may 
have also contributed to these differences, although this 
factor was not assessed in our study. 
Role of initial ejection fraction. Our results agree in part 
with those of Timmis et al. (29), who found improvement in 
left ventricular ejection fraction, independent of infarct site, 
after streptokinase therapy in patients with an initially low 
ejection fraction. They found no significant change in ejec-
tion fraction, regardless of infarct location, in patients who 
had an initial value ::::0.50. This observation may reflect the 
limitations of global ejection fraction in demonstrating myo-
cardial salvage when global ventricular function is normal 
and the area of myocardium at risk is small. 
Global ejection fraction after reperfusion therapy for 
myocardial infarction may be influenced by compensatory 
hyperkinesia in the noninfarct walls (30), myocardial stun-
ning (31), medical therapy and loading conditions. Similar 
limitations have been described (32) for regional wall motion 
analysis. It has been suggested that an alternative approach 
be taken in assessing myocardial salvage (7). 
Ability of technetium-99m isonitrile to quantify infarct size. 
Technetium-99m isonitrile is taken up in normal myocardium 
in proportion to blood flow (14,18). Its ability to quantify 
myocardium at risk acutely and final perfusion defect size 
after myocardial infarction has been previously reported 
(15). Because the quantity of myocardium at risk is inversely 
related to subsequent left ventricular function and survival 
(33), identification of the amount of myocardium at risk is 
therefore critically important. Although it is not known 
whether late technetium-99m isonitrile tomographic imaging 
can distinguish viable but severely ischemic myocardium 
from infarcted myocardium, a distinction that may require 
positron emission tomography (34), results of isonitrile im-
aging have correlated closely with final infarct size in an 
animal model of reperfusion (13). 
Limitations. Because the number of patients in this study 
is small, the power to detect subtle differences between 
groups is low. However, the differences for myocardium at 
risk, salvaged myocardium and global ejection fraction by 
infarct location were highly significant. The perfusion defect 
size obtained with technetium-99m isonitrile imaging is re-
producible to within 6% of the left ventricle (15). Therefore, 
measurement errors will be magnified when the area at risk 
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is small. The salvage index would be expected to be least 
accurate when applied to a small myocardial area at risk. 
Potential limitations of this method include cardiac mo-
tion, nonuniform myocardial thickness and the use of a 
geometric model of the myocardium. Our quantitative 
method will tend to slightly overestimate anterior infarct size 
because the myocardium involved is closer to the chest wall 
and subject to less attenuation and scatter (15,22). However, 
this error is variable and no greater than 4% of the left 
ventricle, which is far smaller than the differences reported 
here. 
Two separate types of reperfusion therapy were employed 
in this study: thrombolysis and primary coronary angio-
plasty. Previous reports (15,19) using technetium-99m isoni-
trile have shown that both treatments reduce left ventricular 
defect size. 
Finally, global ejection fraction after myocardial infarc-
tion has been shown to have important prognostic value 
(35). Technetium-99m isonitrile perfusion defect size, as an 
estimate of infarct size, has correlated well with global 
ejection fraction at hospital discharge in patients after myo-
cardial infarction (15). However, its prognostic value is 
unknown. 
Conclusions. These results indicate that patients with 
inferior infarction generally have a smaller initial and final 
perfusion defect size and higher ejection fraction than do 
those with anterior infarction, although there are overlap-
ping data in the two groups. The absolute benefit of reper-
fusion therapy is significantly greater in patients with ante-
rior infarction because they have more myocardium at risk. 
The relative benefit of reperfusion therapy is reflected by the 
proportion of salvaged myocardium or salvage index. This 
appears to be quite similar regardless of infarct location. 
References 
1. Kennedy JW, Martin GV, Davis KB, et al. The Western Washington 
Intravenous Streptokinase in Acute Myocardial Infarction randomized 
trial. Circulation 1988;77:345-52. 
2. Simoons ML, Serruys PW, van den Brand M, et al. Early thrombolysis in 
acute myocardial infarction: limitation of infarct size and improved 
survival. J Am Coli Cardiol 1986;7:717-28. 
3. The I.S.A.M. Study Group. A prospective trial of intravenous streptoki-
nase in acute myocardial infarction (I.S.A.M.): mortality, morbidity and 
infarct size at 21 days. N Engl J Med 1986;314:1465-71. 
4. O'Rourke M. Baron D, Keough A, et aI. Limitation of myocardial 
infarction by early infusion of recombinant tissue-type plasminogen 
activator. Circulation 1988;77:1311-5. 
5. White HD, Norris RM, Brown MA, et al. Effect of intravenous streptoki-
nase on left ventricular function and early survival after acute myocardial 
infarction. N Engl J Med 1987;317:850-5. 
6. Guerci AD, Gerstenblith G, Brinker JA, et al. A randomized trial of 
intravenous tissue plasminogen activator for acute myocardial infarction 
with subsequent randomization to elective coronary angioplasty. N Engl 
J Med 1987;317:1613-8. 
7. Bates ER, Califf RM, Stack RS, et al. Thrombolysis and Angioplasty in 
Myocardial Infarction (TAMI-1) trial: influence of infarct location on 
arterial patency, left ventricular function and mortality. J Am CoJl Cardiol 
1989;13:12-8. 
8. O'Neill W. Timmis GC. Bourdillon PD, et al. A prospective randomized 
clinical trial of intracoronary streptokinase versus coronary angioplasty 
for acute myocardial infarction. N Engl J Med 1986;314:812-8. 
1308 CHRISTIAN ET AL. 
MYOCARDIAL SALVAGE BY INFARCT LOCATION 
9. Stone GW, Rutherford BD, McConahay DR, et al. Direct coronary 
angioplasty in acute myocardial infarction: outcome in patients with 
single vessel disease. J Am Coli CardioI199O;15:534-43. 
10. O'Keefe JH, Rutherford BD, McConahay DR, et al. Early and late results 
of coronary angioplasty without antecedent thrombolytic therapy for 
acute myocardial infarction. Am J CardioI1989;64:1221-30. 
11. Ritchie JL, Cerquiera M, Maynard C, Davis K, Kennedy JW. Ventricular 
function and infarct size: the Western Washington Intravenous Streptoki-
nase in Myocardial Infarction trial. J Am Coli CardioI1988;1l:689-97. 
12. Verani MS, Jeroudi MO, Mahmarian JJ, et al. Quantification of myocar-
dial infarction during coronary occlusion and myocardial salvage after 
reperfusion using cardiac imaging with technetium-99m hexakis 2-me-
thoxyisobutyl isonitrile. J Am Coli CardioI1988;12:1573-81. 
13. Sinusas AJ, Trautman KA, Bergin 10, et al. Quantification of "area at 
risk" during coronary occlusion and degree of myocardial salvage after 
reperfusion with technetium-99m-methoxyisobutyl-isonitrile. Circulation 
1990;82:1424-37. 
14. Li QS, Frank TL, Franceschi D, Wagner HN, Becker LC. Technetium-
99m-methoxyisobutyl isonitrile (RP30) for quantification of myocardial 
ischemia and reperfusion in dogs. J Nucl Med 1988;29: 1539-48. 
15. Gibbons RJ, Verani MS, Behrenbeck T, et al. Feasibility of tomographic 
technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitriIe imaging for 
the assessment of myocardial area at risk and the elIect of acute treatment 
in myocardial infarction. Circulation 1989;80: 1277-86. 
16. Wackers FJT, Gibbons RJ, Verani MS, et al. Serial quantitative planar 
technetium-99m isonitrile imaging in acute myocardial infarction: efficacy 
for noninvasive assessment of thrombolytic therapy. J Am Coli Cardiol 
1989;14:861-73. 
17. Santoro GM, Bisi G, Sciagra R, Leoncini M, Fazzini PF, Meldolesi U. 
Single photon emission computed tomography with technetium-99m 
hexakis 2-methoxyisobutyl isonitrile in acute myocardial infarction before 
and after thrombolytic treatment: assessment of salvaged myocardium 
and prediction of late functional recovery. J Am Coli Cardiol 1990;15: 
301-14. 
18. Okada RD, Glover D, Gaffney T, Williams S. Myocardial kinetics of 
technetium-99m-hexakis-2-methoxy-2-methylpropyl isonitrile. Circula-
tion 1988;77:491-8. 
19. Behrenbeck T, Pellikka PA, Huber KC, Bresnahan JF, Gersh BJ, 
Gibbons RJ. Primary angioplasty in myocardial infarction: assessment of 
improved myocardial perfusion with technetium-99m isonitrile. J Am Coli 
Cardiol 1991; 17: 365-72. 
20. The TIMI Study Group. The Thrombolysis in Myocardial Infarction trial. 
N Engl J Med 1985;312:932-6. 
21. Vlietstra RE, Holmes DR, Smith HC, Hartzler GO, Orszulak TA. 
Percutaneous transluminal coronary angioplasty. Mayo Clin Proc 1981; 
56:287-93. 
22. O'Connor MK, Hammell TC, Gibbons RJ. In vitro validation ofa simple 
JACC Vol. 17, No.6 
May 1991:1303-8 
tomographic technique for estimation of percent myocardium "at risk" 
following administration of Tc-99m-isonitrile. Eur J Nucl Med 17:69-76. 
23. Callahan RJ, Frolich HW, McKusick KA, Leppo J, Strauss HW. A 
modified method for the in vivo labelling of red blood cells with TC-99m: 
concise communication. J Nucl Med 1981;23:315-8. 
24. Gibbons RJ, Fyke FE III, Clements IP, Lapeyre AC III, Zinsmeister AR, 
Brown ML. Noninvasive identification of severe coronary artery disease 
using exercise radionuclide angiography. J Am Coli CardioI1988;1l:28-
34. 
25. Shah PK, Pichler M, Berman DS, Singh BN, Swan HJe. Left ventricular 
ejection fraction determined by radionuclide ventriculography in the early 
stages of first transmural myocardial infarction. Am J Cardiol 1980;45: 
542-6. 
26. Thanavaro S, Kleiger RE, Province MA, et al. Effect of infarct location 
on the in-hospital prognosis of patients with first transmural myocardial 
infarction. Circulation 1982;66:742-7. 
27. Gruppo Italiano per 10 Studio della Streptochinasi Nell' Infarto Mio-
cardico (GISSI). Effectiveness of intravenous thrombolytic treatment in 
acute myocardial infarction. Lancet 1986;1:397-401. 
28. Rogers WJ, Hood WP Jr, Mantle JA, et al. Return of left ventricular 
function after reperfusion in patients with myocardial infarction: impor-
tance of subtotal stenoses or intact collaterals. Circulation 1984;69:338-
49. 
29. Timmis GC, Westmeer DC, Hauser AM, et al. The influence of infarction 
site and size on the ventricular response to coronary thrombolysis. Arch 
Intern Med 1985;145:2188-93. 
30. Sheehan FH, Mathey DG, Schofer J, Krebber HJ, Dodge HT. Effect of 
interventions in salvaging left ventricular function in acute myocardial 
infarction: a study of intracoronary streptokinase. Am J CardioI1983;52: 
431-8. 
31. Ellis SG, Henschke CI, Sandor T, Wynne J, Braunwald E, Kloner RA. 
Time course of functional and biochemical recovery of myocardium 
salvaged by reperfusion. J Am Coli CardioI1983;1:1047-55. 
32. Sinus as AJ, Hardin NJ, Clements JP, Wackers FJ. Pathoanatomic corre-
lates of regional left ventricular wall motion assessed by equilibrium 
radionuclide angiocardiography: a postmortem correlation. Am J Cardiol 
1984;54:975-81. 
33. Feiring AJ, Johnson MR, Kioschos JM, Kirchner PT, Marcus ML, White 
CWo The importance of the determination of the myocardial area at risk 
in the evaluation of the outcome of acute myocardial infarction in 
patients. Circulation 1987;75:980-7. 
34. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-
motion abnormalities predicted by positron tomography. N Engl J Med 
1986;314:884-8. 
35. The Multicenter Postinfarction Research Group. Risk stratification and 
survival after myocardial infarction. N Engl J Med 1983;309:331-6. 
